SCHEMBL7310554

SCHEMBL7310554

CC[C@H](C)[C@H](NC(=O)OCc1ccccn1)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.55
NPC1 O15118 3/20 0.55
LMNA P02545 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
CTSL P07711 2/20 0.51
CTSB P07858 2/20 0.51
CTSS P25774 2/20 0.51
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
TYR P14679 1/20 0.49
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
CTSK P43235 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
MME P08473 1/20 0.47
ECE1 P42892 1/20 0.47
ADAMTS4 O75173 1/20 0.46
MAPT P10636 1/20 0.46
PGR P06401 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7310548 1.00 RAB9A (0.55) RAB9ANPC1LMNASMN1; SMN2CTSL
SCHEMBL7304466 0.90 RAB9A (0.52) RAB9ANPC1LMNASMN1; SMN2CTSL
SCHEMBL7304462 0.90 RAB9A (0.52) RAB9ANPC1LMNASMN1; SMN2CTSL
SCHEMBL3033874 0.89 NPC1 (0.59) RAB9ANPC1LMNASMN1; SMN2CTSL
SCHEMBL4675990 0.89 NPC1 (0.59) RAB9ANPC1LMNASMN1; SMN2CTSL
SCHEMBL6445930 0.88 NPC1 (0.58) RAB9ANPC1LMNASMN1; SMN2CTSL
SCHEMBL6445922 0.88 NPC1 (0.58) RAB9ANPC1LMNASMN1; SMN2CTSL
SCHEMBL6841181 0.86 NPC1 (0.56) RAB9ANPC1LMNASMN1; SMN2CTSL
SCHEMBL7340196 0.82 CA2 (0.58) LMNASMN1; SMN2CTSLCTSBCTSS
SCHEMBL24734375 0.82 CTSL (0.71) RAB9ALMNACTSLCTSBCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0486948-B1 Retroviral protease inhibiting compounds ABBOTT LAB (US) 2000-10-04 EP disclosed
EP-0997459-A1 Intermediates for preparing retroviral protease inhibiting compounds Abbott Laboratories (US) 2000-05-03 EP disclosed
US-5837873-A PROTECTED OXYDIAMINES ABBOTT LABORATORIES (US) 1998-11-17 US disclosed
US-5807870-A SIDE EFFECT REDUCTION BIOMEGA BOEHRINGER INGELHEIM RESEARCH LTD. (CA) 1998-09-15 US disclosed
US-5648497-A Retroviral protease inhibiting compounds ABBOTT LABORAOTRIES (US) 1997-07-15 US disclosed
US-5616714-A PYRIDYL, THIAZOLYL-SUBSTITUTED AMINO ACID DERIVATIVES ABBOTT LABORATORIES (US) 1997-04-01 US disclosed
US-5614533-A Substituted pipecolinic acid derivatives as HIV protease inhibitors BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH, INC. (CA) 1997-03-25 US disclosed
US-5597926-A Retroviral protease inhibiting compounds ABBOTT LABORATORIES (US) 1997-01-28 US disclosed
US-5554783-A (2R, 3R, 4S, 5S)-3-ACETOXY-2,5-BIS/BENZYLOXYCARBONYLAMINO/ -4-BROMO-1,5-DIPHENYLHEXANE ABBOTT LABORATORIES (US) 1996-09-10 US disclosed
US-5541334-A TREATING HIV ABBOTT LABORATORIES (US) 1996-07-30 US disclosed
EP-0560268-B1 Substituted pipecolinic acid derivatives as HIV protease inhibitors BIO MEGA BOEHRINGER INGELHEIM (CA) 1995-01-04 EP disclosed
US-5354866-A Treating HIV infections ABBOTT LABORATORIES (US) 1994-10-11 US disclosed
WO-1993018003-A1 SUBSTITUED PIPECOLINIC ACID DERIVATIVES AS HIV PROTEASE INHIBITORS BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) 1993-09-16 WO disclosed
EP-0560268-A1 Substituted pipecolinic acid derivatives as HIV protease inhibitors BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) 1993-09-15 EP disclosed
EP-0486948-A2 Retroviral protease inhibiting compounds ABBOTT LABORATORIES (US) 1992-05-27 EP disclosed